$55.8 Million is the total value of Asymmetry Capital Management, L.P.'s 33 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 150.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BAX | New | BAXTER INTERNATIONAL INC | $4,364,000 | – | 52,192 | +100.0% | 7.82% | – |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $2,856,000 | -14.0% | 33,781 | -31.4% | 5.12% | -28.1% |
| CNC | New | CENTENE CORP | $2,793,000 | – | 44,426 | +100.0% | 5.01% | – |
| GH | New | GUARDANT HEALTH INC | $2,753,000 | – | 35,236 | +100.0% | 4.93% | – |
| INSM | Sell | INSMED INC | $2,719,000 | -38.5% | 113,875 | -54.6% | 4.87% | -48.6% |
| MYL | New | MYLAN NV | $2,670,000 | – | 132,855 | +100.0% | 4.79% | – |
| PTCT | Sell | PTC THERAPEUTICS | $2,661,000 | -34.7% | 55,408 | -54.0% | 4.77% | -45.4% |
| TNDM | Buy | TANDEM DIABETES CARE INC | $2,597,000 | +131.9% | 43,559 | +129.3% | 4.66% | +93.9% |
| BIO | Buy | BIO-RAD LABORATORIES-A | $2,350,000 | +25.3% | 6,351 | +12.6% | 4.21% | +4.8% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $1,939,000 | +160.3% | 42,688 | +162.3% | 3.48% | +117.6% |
| UNH | New | UNITEDHEALTH GROUP INC | $1,886,000 | – | 6,414 | +100.0% | 3.38% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $1,721,000 | – | 4,584 | +100.0% | 3.08% | – |
| MYOK | Sell | MYOKARDIA INC | $1,678,000 | -32.8% | 23,023 | -51.9% | 3.01% | -43.8% |
| ABBV | New | ABBVIE INC | $1,675,000 | – | 18,921 | +100.0% | 3.00% | – |
| AERI | New | AERIE PHARMACEUTICALS INC | $1,511,000 | – | 62,507 | +100.0% | 2.71% | – |
| DERM | New | DERMIRA INC | $1,442,000 | – | 81,127 | +100.0% | 2.58% | – |
| XCUR | New | EXICURE INC | $1,430,000 | – | 500,000 | +100.0% | 2.56% | – |
| ESPR | New | ESPERION THERAPEUTICS INC | $1,364,000 | – | 22,872 | +100.0% | 2.44% | – |
| GILD | Sell | GILEAD SCIENCES INC | $1,351,000 | -60.1% | 20,791 | -61.1% | 2.42% | -66.7% |
| BMYRT | New | BRISTOL-MYERS SQUIBB-CVRrts | $1,252,000 | – | 415,931 | +100.0% | 2.24% | – |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $1,235,000 | – | 62,585 | +100.0% | 2.21% | – |
| EHTH | New | EHEALTH INC | $1,230,000 | – | 15,004 | +100.0% | 2.20% | – |
| PTLA | Sell | PORTOLA PHARMACEUTICALS INC | $1,180,000 | -70.7% | 49,431 | -67.1% | 2.12% | -75.5% |
| TWST | Buy | TWIST BIOSCIENCE CORP | $1,141,000 | +25.0% | 54,334 | +42.2% | 2.04% | +4.5% |
| VRAY | New | VIEWRAY INC | $1,081,000 | – | 256,205 | +100.0% | 1.94% | – |
| NCNA | Sell | NUCANA PLC-ADRadr | $975,000 | -18.1% | 159,898 | -2.7% | 1.75% | -31.5% |
| FOLD | New | AMICUS THERAPEUTICS INC | $962,000 | – | 98,718 | +100.0% | 1.72% | – |
| ASND | New | ASCENDIS PHARMA A/S - ADRadr | $911,000 | – | 6,547 | +100.0% | 1.63% | – |
| CYTK | New | CYTOKINETICS INC | $904,000 | – | 85,172 | +100.0% | 1.62% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $896,000 | – | 6,950 | +100.0% | 1.61% | – |
| VAR | New | VARIAN MEDICAL SYSTEMS INC | $843,000 | – | 5,934 | +100.0% | 1.51% | – |
| MRNS | New | MARINUS PHARMACEUTICALS INC | $766,000 | – | 354,853 | +100.0% | 1.37% | – |
| APLS | New | APELLIS PHARMACEUTICALS | $655,000 | – | 21,380 | +100.0% | 1.17% | – |
| PEN | Exit | PENUMBRA INC | $0 | – | -2,700 | -100.0% | -0.78% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -39,273 | -100.0% | -1.56% | – |
| VRCA | Exit | VERRICA PHARMACEUTICALS INC | $0 | – | -74,301 | -100.0% | -2.35% | – |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -377,399 | -100.0% | -2.70% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AG | $0 | – | -37,141 | -100.0% | -3.26% | – |
| AMRN | Exit | AMARIN CORP PLC -ADRadr | $0 | – | -104,509 | -100.0% | -3.40% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -47,453 | -100.0% | -4.02% | – |
| NTRA | Exit | NATERA INC | $0 | – | -63,112 | -100.0% | -4.44% | – |
| DXCM | Exit | DEXCOM INC | $0 | – | -14,770 | -100.0% | -4.72% | – |
| GWPH | Exit | GW PHARMACEUTICALS -ADRadr | $0 | – | -23,729 | -100.0% | -5.85% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INC | $0 | – | -75,011 | -100.0% | -7.80% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.